TNFSF13B and systemic lupus erythematosus: Biologics, like Belimumab (BAFF inhibitor) and Rituximab (CD20 inhibitor), have been developed to specifically reduce the B cell hyperactivity associated with lupus and other autoimmune diseases (4, 56).